Sullivan University College of Pharmacy & Health Sciences announced that it is joining the RAPID Alliance Medications 360 Study, with a goal of transforming how medications and vaccines are delivered in the US from 2022 – 2031. The RAPID Alliance is a multi-stakeholder research consortium founded in the University of Louisville Center for Health Organization Transformation (CHOT), a National Science Foundation-funded research center.
Sullivan University College of Pharmacy & Health Sciences will help lead an “all hands on deck” effort to co-create the RAPID Alliance Medications 360 Framework 2022-2031, a set of transformational strategies and nationally prioritized research agenda for optimizing the use of medications, vaccinations and emerging therapies from 2022-2031.
The project is building on a 2020 research study, conducted during the COVID-19 pandemic, that identified strategic opportunities to improve health and wellbeing for tens of millions of people while reducing US spending on likely-avoidable hospitalizations, emergency department and doctor visits by as much as $528 billion dollars.
Sullivan University College of Pharmacy & Health Sciences, Office of research will contribute to this effort by supporting research and action in areas including state-level strategies for [Kentucky], and special study sections including [RASS-009. Practice / Payment Model Transformation Study Section, RASS-011. Community Pharmacy Transformation Study Section, and any other sections we can help with).
Dr. Abeer Al-Ghananeem, Director of Research, who is helping lead this project for Sullivan University College of Pharmacy & Health Sciences, said: “We are delighted to be part of this important national effort to co-create new, actionable strategies and research priorities to optimize medication and vaccine use for US populations.”
[Lucinda Maine, Chief Executive Officer of the American Association of Colleges of Pharmacy (AACP), a founding member of the RAPID Alliance Practice Council, said: “We are delighted to see this progress. We believe national and state strategies driven by research by a multi-university research consortia like this is key to optimizing medication use for US populations in the next decade.”
Participating universities include American University, Belmont University, Binghamton University, California Northstate University, Chapman University, Ferris State University, Howard University, Lipscomb University, Loma Linda University, Long Island University, Marshall University, Medical College Wisconsin, Mercer University, North Dakota State, Oregon Health & Science University, Oregon State University, South Dakota State University, Sullivan University, Temple University, University of Arkansas, University of Cincinnati, University of Colorado, University of Georgia, University of Hawaii Hilo, University of Houston, University of Kentucky, University of Louisville, University of Michigan, University of Mississippi, University of Nebraska, University of Nevada Reno, University of Pittsburgh, University of Rhode Island, University of South Carolina, University of Tennessee, Washington State University, Wayne State University and Western University.
The consortium plans to add up to 30 additional universities in the coming months to support research and action in all 50 states.